Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
PHAT 11.04.2024
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December:
Guggenheim’s Inaugural Healthcare Innovation Conferencein Boston, MADate: Tuesday, November 12, 2024Live Webcast: 9:30 am ETManagement to participate in one-on-one meetings throughout the conference
Stifel 2024 Healthcare Conferencein New York, NYDate: Monday, November 18, 2024Live Webcast: 1:15 pm ETManagement to participate in one-on-one meetings throughout the conference
Jefferies London Healthcare Conferencein London, UKDate: Wednesday, November 20, 2024Management to participate in one-on-one meetings throughout the conference
7th Annual Evercore HealthCONx Conferencein Coral Gables, FLDate: Tuesday, December 3, 2024Live Webcast: 2:10 pm ETManagement to participate in one-on-one meetings throughout the conference
To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website athttps://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.
About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA®(vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA®TRIPLE PAK®(vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA®DUAL PAK®(vonoprazan tablets, amoxicillin capsules) for the treatment ofH. pyloriinfection in adults. For more information about Phathom, visit the company’s website atwww.phathompharma.comand follow onLinkedInandX.
MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.comINVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com
© 2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
